Company Overview

Fulgent Genetics, Inc. is a U.S.-based molecular diagnostics company that develops and provides genetic testing services for clinical, research, and commercial applications. The company operates within the genetic testing, molecular diagnostics, and precision medicine industries, offering next-generation sequencing (NGS)–based tests that support disease diagnosis, carrier screening, oncology profiling, and rare disease identification. Its core revenue is generated from laboratory-developed tests and diagnostic services provided to healthcare providers, hospitals, government agencies, and life sciences organizations.

The company is known for its flexible testing platform, which allows physicians to customize gene panels rather than relying solely on fixed test menus. This adaptability, combined with an integrated laboratory and bioinformatics infrastructure, has been cited as a strategic advantage. Fulgent Genetics was founded in 2011 and grew initially through hereditary disease testing before expanding significantly during the COVID-19 pandemic, when large-scale testing contracts became a major but time-limited revenue driver. Post-pandemic, the company has refocused on long-term growth areas such as oncology, reproductive health, and population-scale genomics.

Business Operations

Fulgent Genetics generates revenue primarily through its Clinical Diagnostic Testing and Precision Diagnostics business lines, which include hereditary disease testing, oncology testing, carrier screening, and pharmacogenomics. During the COVID-19 pandemic, COVID-19 Testing Services became a distinct and material operating segment, although this revenue has since declined substantially. The company operates a CLIA-certified and CAP-accredited laboratory and controls its own proprietary testing and bioinformatics workflow, enabling rapid test development and scalability.

Operations are primarily based in the United States, with international reach through testing services and research collaborations. The company owns and operates Fulgent Therapeutics LLC, which focuses on advanced molecular diagnostics and technology development. It has also established infrastructure to support large institutional and government clients, including public health agencies. No material joint ventures have been consistently reported as core to ongoing operations, and partnerships are generally service-based rather than equity-based.

Strategic Position & Investments

Strategically, Fulgent Genetics is positioning itself toward higher-margin, specialized genetic testing markets following the normalization of pandemic-related demand. Growth initiatives include expansion of oncology testing menus, broader adoption of comprehensive carrier screening, and increased penetration of health system–wide genetic programs. The company has emphasized disciplined capital allocation, leveraging cash generated during peak COVID-19 operations to support technology investment and selective acquisitions.

Notable investments include the acquisition of Inform Diagnostics, a pathology services company, which expanded Fulgent’s capabilities beyond genetics into anatomic pathology and diversified its diagnostic offerings. The company has also invested in automation, data analytics, and scalable laboratory infrastructure to support population health initiatives and large-volume testing programs. Emerging areas of focus include integrated diagnostics and multi-omics approaches, although revenue contribution from these areas remains limited based on publicly available data.

Geographic Footprint

Fulgent Genetics is headquartered in California, with primary laboratory and operational facilities located in the United States. The company’s core customer base is domestic, including healthcare providers, hospitals, and government agencies across multiple states. Its U.S. presence remains the dominant contributor to revenue.

Internationally, the company supports testing for global clients through sample logistics and research collaborations, though it does not report extensive owned laboratory infrastructure outside the United States. Its international exposure is primarily service-driven rather than asset-heavy, with limited disclosure on standalone foreign operations. Based on available public filings, international revenue represents a smaller portion of total sales compared to domestic operations.

Leadership & Governance

Fulgent Genetics was founded by Ming Hsieh, who has played a central role in shaping the company’s technology-driven and operationally flexible strategy. Leadership has emphasized scalable diagnostics, rapid test development, and maintaining control over core laboratory and informatics capabilities. The governance structure reflects a founder-led organization with a focus on long-term investment and conservative balance sheet management.

Key executives include:

• Ming Hsieh – Chairman of the Board and Chief Executive Officer
• Brandon Perth – Chief Operating Officer
• Paul Kim – Chief Financial Officer
• Shishir Thakur – Chief Commercial Officer

Public disclosures consistently identify these individuals as responsible for strategic execution, financial oversight, and commercial expansion. Where executive roles or titles vary slightly across filings, data is consistent in substance but may differ in presentation based on reporting period.